Description
Self-amplifying RNA (saRNA) can use its own RNA sequence as a template for self-replication, thereby achieving the same level of protein expression as traditional mRNA at lower doses. This extends the presence of the antigen protein in the body, further enhancing the vaccine's immune efficacy. Firefly Luciferase saRNA is a self-amplifying RNA synthesized in vitro. It features a replicase expression sequence structure derived from the Venezuelan equine encephalitis virus (VEEV), enabling self-replication both in vivo and in vitro. This allows for low-dose, high-level, and long-lasting expression of the target gene. This product encodes luciferase derived from the North American firefly (Photinus pyralis), with point mutations introduced based on the wild-type sequence, significantly enhancing the protein's thermal stability and pH tolerance. Upon expression in vivo or in vitro, it catalyzes the substrate to emit intense bioluminescence. This product is a saRNA synthesized in vitro using the T7 RNA Polymerase 2.0 (Novoprotein, Cat.No.: E122). It features a 5' Cap 1 structure and a 3' poly(A) tail, with a fragment length of 9723 nucleotides (nt)